Target's General Information
Target ID T46128
Target Name Melanocytes lineage-specific antigen GP100 (PMEL)
Synonyms Silver locus protein homolog; SILV; Premelanosome protein; PMEL17; P100; P1; Melanomaassociated ME20 antigen; Melanoma-associated ME20 antigen; Melanocyte protein Pmel 17; Melanocyte protein PMEL; Mbeta; ME20S; ME20M; ME20-M; D12S53E
Target Type Clinical trial
Gene Name PMEL
UniProt ID PMEL_HUMAN
Target's Expression Profile in Disease Related Tissue between Patients and Normal People
Disease Melanoma
Example drug Melanoma vaccine Phase 3 [1], [2], [3]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: 1.89
Z-score: 1.06
P-value: 1.08E-03
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target's Expression Profile across Various Tissues of Healthy Individual
References
REF 1 ClinicalTrials.gov (NCT00036816) Vaccine Therapy in Treating Patients With Melanoma of the Eye. U.S. National Institutes of Health.
REF 2 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 3 NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.